已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Biologic switching and relapses during biologic therapy in AQP4-IgG-positive NMOSD: a real-world study

医学 多发性硬化 免疫学 生物制剂 肿瘤科 免疫疗法 内科学 梅德林 奥克列珠单抗 抗体疗法 临床试验 疾病 纳塔利祖玛 自身免疫性疾病 免疫系统 重症监护医学
作者
Ayano Matsuyoshi,Koji Shinoda,Hajime Takeuchi,Yukiko Inamori,Ryo Kurasawa,Keisuke Mizutani,Yuu‐ichi Kira,Kazunori Iwao,Mitsuru Watanabe,Katsuhisa Masaki,Noriko Isobe
出处
期刊:Multiple sclerosis and related disorders [Elsevier BV]
卷期号:117: 108044-108044
标识
DOI:10.1016/j.msard.2026.108044
摘要

BACKGROUND: Biologics are highly efficacious in preventing relapses of anti-aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorders (NMOSD). However, real-world data regarding biologic switching and on-treatment breakthrough relapses remain limited. METHODS: We retrospectively investigated the treatment history of 163 patients with AQP4-IgG-positive NMOSD who visited our hospitals between 2000 and 2026. Biologic switching was defined as a transition within 2 months from one biologic to another treatment with a different therapeutic target. Among those who underwent biologic switching, reasons for switching and Expanded Disability Status Scale (EDSS) score at switching were assessed. Relapses occurring during biologic treatment other than rituximab and tocilizumab were also analyzed. RESULTS: A total of 91 (55.8%) patients received at least one biologic. Among them, 17 patients underwent biologic switching after a median treatment duration of 1.5 years. The most frequent transitions were satralizumab to inebilizumab (n = 5), satralizumab to ravulizumab (n = 3), and ravulizumab to inebilizumab (n = 3). Switching was primarily driven by adverse events in satralizumab-treated patients, and by treatment burden and individual circumstances in ravulizumab-treated patients. Breakthrough relapses were documented in 7 patients: 6 during 131.1 person-years of satralizumab (0.05 events/person-year) and one during 61.9 person-years of ravulizumab (0.02 events/person-year), whereas no relapses occurred during 40.0 person-years of inebilizumab. Two patients switched biologics following breakthrough relapses. CONCLUSIONS: Biologic switching was primarily driven by adverse events, treatment burden, and individual circumstances rather than inadequate disease control. Breakthrough relapses during biologic treatment were uncommon and did not always result in switching biologics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
111发布了新的文献求助10
1秒前
suuuye完成签到,获得积分10
2秒前
平常的秋白完成签到,获得积分20
2秒前
无私的沁完成签到 ,获得积分10
4秒前
不去明知山完成签到 ,获得积分0
7秒前
1111完成签到,获得积分10
7秒前
Ashley完成签到 ,获得积分10
8秒前
无极微光的应助被霖霖采纳,获得20
10秒前
11秒前
12秒前
沉默皮卡丘完成签到 ,获得积分10
13秒前
汪欣怡完成签到 ,获得积分10
13秒前
14秒前
CodeCraft的应助被爱you采纳,获得10
15秒前
科研通AI6.4的应助被hulai采纳,获得10
15秒前
CHean发布了新的文献求助20
16秒前
hanshishengye完成签到 ,获得积分0
18秒前
18秒前
21秒前
成就舞仙完成签到,获得积分10
23秒前
23秒前
大力的无声完成签到,获得积分10
24秒前
平常映雁发布了新的文献求助10
24秒前
lb完成签到,获得积分10
26秒前
27秒前
小二郎的应助被Clearday采纳,获得10
27秒前
二呆熊发布了新的文献求助10
28秒前
小丑完成签到,获得积分10
28秒前
LUYAO1完成签到 ,获得积分10
28秒前
xl_c完成签到 ,获得积分10
28秒前
28秒前
K2C完成签到,获得积分10
33秒前
ZM完成签到,获得积分10
33秒前
Ava的应助被二呆熊采纳,获得10
35秒前
小巧的白容完成签到,获得积分10
35秒前
36秒前
无花果的应助被Flynn采纳,获得10
36秒前
科研通AI2S的应助被科研通管家采纳,获得50
36秒前
lukou关注了科研通微信公众号
37秒前
Nole的应助被科研通管家采纳,获得10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179547
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807373
捐赠科研通 7775016
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478760